REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
8.25
+0.04 (0.49%)
At close: Jul 1, 2025, 4:00 PM
8.23
-0.02 (-0.24%)
After-hours: Jul 1, 2025, 4:04 PM EDT
REGENXBIO Stock Forecast
Stock Price Forecast
The 8 analysts that cover REGENXBIO stock have a consensus rating of "Strong Buy" and an average price target of $31.75, which forecasts a 284.85% increase in the stock price over the next year. The lowest target is $12 and the highest is $52.
Price Target: $31.75 (+284.85%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for REGENXBIO stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 4 | 3 | 3 | 3 |
| Buy | 7 | 7 | 4 | 4 | 4 | 4 |
| Hold | 1 | 2 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 9 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $52 | Strong Buy | Maintains | $52 | +530.30% | Jun 9, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $14 → $12 | Hold | Maintains | $14 → $12 | +45.45% | Apr 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $34 | Strong Buy | Reiterates | $34 | +312.12% | Mar 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $34 | Strong Buy | Reiterates | $34 | +312.12% | Mar 20, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $52 | Strong Buy | Maintains | $52 | +530.30% | Mar 20, 2025 |
Financial Forecast
Revenue This Year
355.88M
from 83.33M
Increased by 327.08%
Revenue Next Year
293.35M
from 355.88M
Decreased by -17.57%
EPS This Year
-0.05
from -4.59
EPS Next Year
-2.47
from -0.05
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 516.6M | 507.1M | 571.2M | ||
| Avg | 355.9M | 293.4M | 334.9M | ||
| Low | 147.0M | 184.2M | 214.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 520.0% | 42.5% | 94.7% | ||
| Avg | 327.1% | -17.6% | 14.1% | ||
| Low | 76.4% | -48.2% | -27.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.84 | 0.96 | -0.92 | ||
| Avg | -0.05 | -2.47 | -2.65 | ||
| Low | -3.29 | -5.36 | -4.01 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.